知柏地黄汤加减治疗不明原因女童外周性性早熟临床研究
|
摘要
目的:观察知柏地黄汤加减治疗不明原因女童外周性性早熟的临床疗效。方法:选取50例不明原因外周性性早熟女童为研究对象,将30例接受知柏地黄汤加减治疗的患儿设为观察组,将只接受临床观察随访的20例患儿设为对照组。观察2组患儿治疗前后的生长发育情况、血清性激素水平,比较2组临床疗效。结果:治疗后,观察组身高增速大于对照组,差异有统计学意义(P <0.05);观察组骨龄变化与对照组比较,差异无统计学意义(P> 0.05)。治疗后,观察组黄体生成素(LH)、卵泡刺激素(FSH)、雌二醇(E_2)及对照组LH、E2水平均较治疗前降低,差异均有统计学意义(P <0.05);观察组LH、FSH及E_2水平均低于对照组,差异均有统计学意义(P <0.05)。总有效率观察组86.7%,对照组65.0%,2组比较,差异有统计学意义(P <0.05)。结论:知柏地黄汤加减治疗不明原因女童外周性性早熟临床疗效满意。
Objective: To observe the clinical effect of modified Zhibai Dihuang tang for girls with peripheral precocious puberty induced by unknown causes. Methods: Selected 50 cases of girls with peripheral precocious puberty induced by unknown causes as the study subjects. 30 cases of these girls who received Zhibai Dihuang tang were treated as the observation group,while other 20 cases who were only given follow-up for clinical observation were enrolled in the control group. Observed the growth and development and serum sex hormone levels of the two groups before and after treatment,and compared the clinical effect of the two groups. Results: After treatment, the growth rate of height in the observation group was higher than that of the control group, difference being significant(P < 0.05); there was no significant difference being found in the comparison of the bone age between the observation group and the control group(P > 0.05). After treatment,the levels of luteinizing hormone(LH),follicle stimulating hormone(FSH),estradiol(E_2) in the observation group and LH and E_2 in the control group were all lower than those before treatment,differences being significant(P < 0.05);the levels of LH, FSH and E_2 in the observation group were lower than those in the control group, differences being significant(P <0.05). The total effective was 86.7% in the observation group and 65.0% in the control group, compared the two groups,difference being significant(P < 0.05). Conclusion:The application of modified Zhibai Dihuang tang has positive clinical effect in treating girls with peripheral precocious puberty induced by unknown causes.
Objective: To observe the clinical effect of modified Zhibai Dihuang tang for girls with peripheral precocious puberty induced by unknown causes. Methods: Selected 50 cases of girls with peripheral precocious puberty induced by unknown causes as the study subjects. 30 cases of these girls who received Zhibai Dihuang tang were treated as the observation group,while other 20 cases who were only given follow-up for clinical observation were enrolled in the control group. Observed the growth and development and serum sex hormone levels of the two groups before and after treatment,and compared the clinical effect of the two groups. Results: After treatment, the growth rate of height in the observation group was higher than that of the control group, difference being significant(P < 0.05); there was no significant difference being found in the comparison of the bone age between the observation group and the control group(P > 0.05). After treatment,the levels of luteinizing hormone(LH),follicle stimulating hormone(FSH),estradiol(E_2) in the observation group and LH and E_2 in the control group were all lower than those before treatment,differences being significant(P < 0.05);the levels of LH, FSH and E_2 in the observation group were lower than those in the control group, differences being significant(P <0.05). The total effective was 86.7% in the observation group and 65.0% in the control group, compared the two groups,difference being significant(P < 0.05). Conclusion:The application of modified Zhibai Dihuang tang has positive clinical effect in treating girls with peripheral precocious puberty induced by unknown causes.
引文
[1]中华人民共和国卫生部.性早熟诊疗指南(试行)[卫办医政发(195)号][J].中国儿童保健杂志,2011,19(4):390-392.
[2]马华梅.儿童性早熟药物治疗进展[J].实用儿科临床杂志,2011,26(8):553-557.
[3]林亦鑫.中医辨证治疗女童性早熟进展[J].医学综述,2014,20(6):1093-1095.
[4]汪受传.中医儿科学[M].北京:中国中医药出版社,2007:265-271.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:388-390.
[2]马华梅.儿童性早熟药物治疗进展[J].实用儿科临床杂志,2011,26(8):553-557.
[3]林亦鑫.中医辨证治疗女童性早熟进展[J].医学综述,2014,20(6):1093-1095.
[4]汪受传.中医儿科学[M].北京:中国中医药出版社,2007:265-271.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:388-390.